KR102280530B1 - 자폐증 스펙트럼 장애의 치료에 사용되는 도파민 d3 수용체 길항제로서의 크로모네 유도체 - Google Patents
자폐증 스펙트럼 장애의 치료에 사용되는 도파민 d3 수용체 길항제로서의 크로모네 유도체 Download PDFInfo
- Publication number
- KR102280530B1 KR102280530B1 KR1020167015313A KR20167015313A KR102280530B1 KR 102280530 B1 KR102280530 B1 KR 102280530B1 KR 1020167015313 A KR1020167015313 A KR 1020167015313A KR 20167015313 A KR20167015313 A KR 20167015313A KR 102280530 B1 KR102280530 B1 KR 102280530B1
- Authority
- KR
- South Korea
- Prior art keywords
- dopamine
- asd
- treatment
- acid
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13306726.4 | 2013-12-13 | ||
| EP13306726 | 2013-12-13 | ||
| PCT/EP2014/077635 WO2015086836A1 (en) | 2013-12-13 | 2014-12-12 | A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160088886A KR20160088886A (ko) | 2016-07-26 |
| KR102280530B1 true KR102280530B1 (ko) | 2021-07-21 |
Family
ID=49883003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020167015313A Expired - Fee Related KR102280530B1 (ko) | 2013-12-13 | 2014-12-12 | 자폐증 스펙트럼 장애의 치료에 사용되는 도파민 d3 수용체 길항제로서의 크로모네 유도체 |
Country Status (29)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009270823B2 (en) | 2008-07-16 | 2014-07-17 | Richter Gedeon Nyrt. | Pharmaceutical formulations containing dopamine receptor ligands |
| US11274087B2 (en) | 2016-07-08 | 2022-03-15 | Richter Gedeon Nyrt. | Industrial process for the preparation of cariprazine |
| HU231500B1 (hu) | 2019-04-10 | 2024-04-28 | Richter Gedeon Nyrt | Karbamoil-ciklohexán származékok autizmus spektrum betegség kezelésére |
| US11547707B2 (en) | 2019-04-10 | 2023-01-10 | Richter Gedeon Nyrt. | Carbamoyl cyclohexane derivatives for treating autism spectrum disorder |
| CA3152645A1 (en) * | 2019-09-11 | 2021-03-18 | Oxford BioDynamics PLC | Diagnostic chromosome marker |
| KR20220021157A (ko) | 2020-08-13 | 2022-02-22 | 원광대학교산학협력단 | 옥시토신 호르몬 증가효과를 갖는 자폐스펙트럼장애 아동 개선용 교육시스템 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2682953B1 (fr) * | 1991-10-23 | 1995-04-21 | Inst Nat Sante Rech Med | Nouveaux derives de naphtamides, leur procede de preparation et leur application dans le domaine therapeutique. |
| DE4229880A1 (de) * | 1992-09-04 | 1994-03-31 | Knauf Siegfried | Medikament bzw. Medikamentenzusammensetzung |
| CA2346689A1 (en) | 1998-10-08 | 2000-04-20 | Gregor James Macdonald | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| WO2006034187A2 (en) * | 2004-09-20 | 2006-03-30 | Mount Sinai School Of Medicine | Use of memantine (namenda) to treat autism, compulsivity, and impulsivity |
| EP2263665A1 (en) * | 2009-06-02 | 2010-12-22 | Pharnext | New compositions for treating CMT and related disorders |
| FR2949465B1 (fr) * | 2009-09-01 | 2011-08-12 | Pf Medicament | Derives chromones, leur procede de preparation et leurs applications therapeutiques |
| WO2011150380A1 (en) * | 2010-05-28 | 2011-12-01 | Xenoport, Inc. | Methods of treatment of fragile x syndrome, down's syndrome, autism and related disorders |
| WO2012157463A1 (en) * | 2011-05-13 | 2012-11-22 | Semiconductor Energy Laboratory Co., Ltd. | Semiconductor device |
| FR2976179A1 (fr) * | 2011-06-09 | 2012-12-14 | Pf Medicament | Utilisation de la carpipramine dans le traitement de troubles psychiatriques et du developpement chez l'enfant et l'adolescent |
-
2014
- 2014-12-12 PT PT148124654T patent/PT3079688T/pt unknown
- 2014-12-12 TN TN2016000213A patent/TN2016000213A1/en unknown
- 2014-12-12 MA MA39076A patent/MA39076A1/fr unknown
- 2014-12-12 RS RS20180196A patent/RS56931B1/sr unknown
- 2014-12-12 PL PL14812465T patent/PL3079688T3/pl unknown
- 2014-12-12 SI SI201430603T patent/SI3079688T1/en unknown
- 2014-12-12 NZ NZ720868A patent/NZ720868A/en not_active IP Right Cessation
- 2014-12-12 WO PCT/EP2014/077635 patent/WO2015086836A1/en not_active Ceased
- 2014-12-12 HU HUE14812465A patent/HUE036035T2/hu unknown
- 2014-12-12 RU RU2019104946A patent/RU2019104946A/ru unknown
- 2014-12-12 LT LTEP14812465.4T patent/LT3079688T/lt unknown
- 2014-12-12 US US15/103,470 patent/US10028948B2/en active Active
- 2014-12-12 EP EP14812465.4A patent/EP3079688B1/en not_active Not-in-force
- 2014-12-12 MX MX2016007612A patent/MX372922B/es active IP Right Grant
- 2014-12-12 JP JP2016538587A patent/JP6419826B2/ja not_active Expired - Fee Related
- 2014-12-12 HR HRP20180323TT patent/HRP20180323T8/hr unknown
- 2014-12-12 MY MYPI2016702136A patent/MY172937A/en unknown
- 2014-12-12 ES ES14812465.4T patent/ES2657706T3/es active Active
- 2014-12-12 AU AU2014363428A patent/AU2014363428B2/en not_active Ceased
- 2014-12-12 CA CA2932791A patent/CA2932791C/en active Active
- 2014-12-12 UA UAA201607311A patent/UA117271C2/uk unknown
- 2014-12-12 CN CN201480066587.4A patent/CN105792824B/zh not_active Expired - Fee Related
- 2014-12-12 NO NO14812465A patent/NO3079688T3/no unknown
- 2014-12-12 RU RU2016125829A patent/RU2686110C1/ru active
- 2014-12-12 BR BR112016012552A patent/BR112016012552A8/pt not_active Application Discontinuation
- 2014-12-12 KR KR1020167015313A patent/KR102280530B1/ko not_active Expired - Fee Related
- 2014-12-12 DK DK14812465.4T patent/DK3079688T3/da active
-
2016
- 2016-06-02 IL IL245996A patent/IL245996B/en active IP Right Grant
- 2016-06-12 SA SA516371298A patent/SA516371298B1/ar unknown
-
2018
- 2018-02-09 CY CY20181100159T patent/CY1119907T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ross et al. | Huntington disease | |
| AU2014363428B2 (en) | A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder | |
| Costa et al. | Prospects for improving brain function in individuals with Down syndrome | |
| Lee et al. | Is oxytocin application for autism spectrum disorder evidence-based? | |
| US20250235443A1 (en) | Use of roluperidone to treat negative symptoms and disorders, increase neuroplasticity, and promote neuroprotection | |
| Cao et al. | ErbB4 deletion in noradrenergic neurons in the locus coeruleus induces mania-like behavior via elevated catecholamines | |
| JP7277458B2 (ja) | 神経学的疾患を治療するための方法および組成物 | |
| US20230226019A1 (en) | Mdma enantiomers | |
| US20130164367A1 (en) | Treatment of neurodegenerative disease with creb-binding protein | |
| Kohlschütter et al. | Epilepsy in neuronal ceroid lipofuscinoses | |
| OA17906A (en) | A chromone derivative as a dopamine D3 receptor antagonist for its use for the treatment of autism spectrum disorder. | |
| US20240009180A1 (en) | Medicine for alleviating neuropathic pain | |
| HK1223563B (en) | A chromone derivative as a dopamine d3 receptor antagonist for its use for the treatment of autism spectrum disorder | |
| RU2812786C2 (ru) | Применение ролуперидона для лечения негативных симптомов и заболеваний, повышения нейропластичности и содействия нейрозащите | |
| Fonteneau et al. | Tilted striatofugal balance and beneficial effects of facilitating mGlu4 receptor activity in the Fmr1-/-mouse model of Fragile X Syndrome | |
| Konttinen et al. | Microglial amyloid beta clearance is driven by PIEZO1 channels | |
| TW202307217A (zh) | 用於診斷及治療於染色體2的2:107,510,000至107,540,000位點具有單一核苷酸多型性的個體的方法 | |
| CN121604971A (zh) | 用于治疗与焦虑症相关的认知障碍的hip/pap蛋白或其衍生物 | |
| Alfei Palloni et al. | Learning experience determines the fate of fear memories after post-training manipulations | |
| Lopez et al. | P. 4. a. 006 Cytokines in patients with fibromyalgia illness and anxious-depressive symptoms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| A201 | Request for examination | ||
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20240717 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20240717 |